Back
CCO Premium Access

High incidence of immune checkpoint inhibitor therapy related subclinical cardiac dysfunction in patients with extracardiac immune related adverse events

Session: Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy
Topic: Stratification, Prevention and Monitoring
Speaker: Associate Professor R. Mincu (Essen, DE)
Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

Like

About the speaker

Associate Professor Raluca-Ileana Mincu

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)
0 follower

8 more presentations in this session

Right ventricular dysfunction in hematologic patients exposed to Chimeric Antigen Receptor (CAR)-T cells therapy: results from the prospective CARdio-TOX study.

Speaker: Doctor L. Amore (Rome, IT)

Access
Abstract
Slides
Like
Thumbnail

Abatacept vs. conventional therapy in immune checkpoint inhibitor-associated myocarditis

Speaker: Doctor T. Imaoka (Kashiwa, JP)

Access
Abstract
Slides
Like
Thumbnail

Cardiac dysfunction in patients with kidney cancer receiving immunotherapy

Speaker: Doctor M. Spisarova (Olomouc, CZ)

Access
Abstract
Slides
Like
Thumbnail

Mycophenolate mofetil as second-line therapy for steroid-refractory ICI-induced myocarditis

Speaker: Doctor S. Jimenez-Marrero (Barcelona, ES)

Access
Abstract
Slides
Like
Thumbnail

Immune checkpoint inhibition increases aortic inflammation on 18F-FDG PET/CT: a retrospective cohort study in patients with Merkel cell carcinoma receiving avelumab

Speaker: Miss A. Strijdhorst (Amsterdam, NL)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy

Speakers: Associate Professor R. Mincu, Doctor L. Amore, Doctor T. Imaoka, Doctor M. Spisarova, Doctor S. Jimenez-Marrero...
Access
Like
Thumbnail

About the event

Image

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources